UDkt. Daniel J. DeAngelo

UDkt. DeAngelo uthole i-MD yakhe kanye ne-PhD ku-Albert Einstein College of Medicine ngo-1993, kwalandelwa ukuhlala kwezokwelapha zangaphakathi eMassachusetts General Hospital. Usebenze ubudlelwano bomtholampilo ku-hematology kanye ne-oncology e-Brigham and Women's Hospital kanye naseDana-Farber Cancer Institute, lapho ajoyina khona abasebenzi ngo-1999.

Isitifiketi Sebhodi:

• I-Hematology, 2000
• Imithi yangaphakathi
• I-Medical Oncology, 1999

Ukuhlanganyela:

• Isibhedlela iBrigham kanye neSibhedlela Sabesifazane, I-Hematology & Oncology

Ukuhlala kabusha:

• I-Massachusetts General Hospital, Imithi Yangaphakathi

Isikole Sezokwelapha:

• I-Albert Einstein College of Medicine

• Ukwelashwa kwe-CAR T-cell
• AmaLeukemias
• I-Mastocytosis
• Ama-syndromes we-Myelodysplastic
• Izinkinga ze-Myeloproliferative

• I-Leukemia, i-Acute Lymphoblastic (BONKE)
• Umdlavuza wegazi, Acute Myeloid (AML)
• Umdlavuza wegazi, Chronic Myelogenous (CML)
• AmaLeukemias
• I-Myelodysplastic Syndromes (MDS)
• Ama-Neoplasms we-Myeloproliferative (MPNs)

The Adult Leukemia Group is responsible for the diagnosis and treatment of patients with acute and chronic leukemia, myelodysplastic syndrome (MDS), and other stem cell hematopoietic disorders. Our clinical research centers around phase I, II, and III izivivinyo zokwelashwa in these patients. We recently studied a series of patients with idiopathic hypereosinophilic syndrome (IHES). In collaboration with Drs. Cools and Gilliland, we identified a target gene, the FIP1L1-PDGFRA fusion gene, which is a consequence of an interstitial chromosomal deletion. This finding has led to an explanation of the molecular basis of IHES.

Iqembu lethu njengamanje lisebenzela ukuthuthukiswa kwamangqamuzana amancane okwelapha i-leukemia eyingozi futhi engapheli kanye ne-myelodysplasia. Sihlola ama-molecule amancane ambalwa ezigulini ezine-leukemia e-acute myelogenous ebuyele emuva noma e-refractory, sifunda izinhlanganisela ze-PKC-412, CEP-701, ne-MLN-518 ezivimbela ngokuqondile i-FLT3. Ukuguqulwa kofuzo ku-FLT3 gene, ehlanganisa i-receptor tyrosine kinase, kucatshangwa ukuthi kunikeza ukubikezela okubi ezigulini ezine-acute myelogenous leukemia.

We also have clinical trials under way that test histone deacetylase inhibitors in advanced hematologic malignancies. Our approach is to bring novel therapeutic agents to the forefront in the treatment of patients with acute and chronic leukemia, MDS, and myeloproliferative disorders. In addition, our group has been focused on the treatment of i-leukemia enamandla ye-lymphoblastic (ALL). We are the lead coordinating site for a large clinical trial using dose-intense pediatric-like regimens for adult patients with ALL. We are also testing novel Notch inhibitor molecules for patients with relapsed or refractory T-cell ALL.